Literature DB >> 23897499

Polycomb group proteins and MYC: the cancer connection.

Leonidas Benetatos1, George Vartholomatos, Eleftheria Hatzimichael.   

Abstract

Polycomb group proteins (PcGs) are transcriptional repressors involved in physiological processes whereas PcG deregulation might result in oncogenesis. MYC oncogene is able to regulate gene transcription, proliferation, apoptosis, and malignant transformation. MYC deregulation might result in tumorigenesis with tumor maintenance properties in both solid and blood cancers. Although the interaction of PcG and MYC in cancer was described years ago, new findings are reported every day to explain the exact mechanisms and results of such interactions. In this review, we summarize recent data on the PcG and MYC interactions in cancer, and the putative involvement of microRNAs in the equation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23897499     DOI: 10.1007/s00018-013-1426-x

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  137 in total

Review 1.  MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship.

Authors:  Amy E Pasquinelli
Journal:  Nat Rev Genet       Date:  2012-03-13       Impact factor: 53.242

Review 2.  Genomics of microRNA.

Authors:  V Narry Kim; Jin-Wu Nam
Journal:  Trends Genet       Date:  2006-01-30       Impact factor: 11.639

3.  Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF.

Authors:  J J Jacobs; B Scheijen; J W Voncken; K Kieboom; A Berns; M van Lohuizen
Journal:  Genes Dev       Date:  1999-10-15       Impact factor: 11.361

4.  c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells.

Authors:  Zuqin Nie; Gangqing Hu; Gang Wei; Kairong Cui; Arito Yamane; Wolfgang Resch; Ruoning Wang; Douglas R Green; Lino Tessarollo; Rafael Casellas; Keji Zhao; David Levens
Journal:  Cell       Date:  2012-09-28       Impact factor: 41.582

Review 5.  MYC in oncogenesis and as a target for cancer therapies.

Authors:  Ami Albihn; John Inge Johnsen; Marie Arsenian Henriksson
Journal:  Adv Cancer Res       Date:  2010       Impact factor: 6.242

Review 6.  Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants.

Authors:  Jr-Shiuan Yang; Eric C Lai
Journal:  Mol Cell       Date:  2011-09-16       Impact factor: 17.970

7.  Human inactive X chromosome is compacted through a PRC2-independent SMCHD1-HBiX1 pathway.

Authors:  Ryu-Suke Nozawa; Koji Nagao; Ken-Taro Igami; Sachiko Shibata; Natsuko Shirai; Naohito Nozaki; Takashi Sado; Hiroshi Kimura; Chikashi Obuse
Journal:  Nat Struct Mol Biol       Date:  2013-03-31       Impact factor: 15.369

Review 8.  Myc transcription factors: key regulators behind establishment and maintenance of pluripotency.

Authors:  Keriayn Smith; Stephen Dalton
Journal:  Regen Med       Date:  2010-11       Impact factor: 3.806

9.  TrxG and PcG proteins but not methylated histones remain associated with DNA through replication.

Authors:  Svetlana Petruk; Yurii Sedkov; Danika M Johnston; Jacob W Hodgson; Kathryn L Black; Sina K Kovermann; Samantha Beck; Eli Canaani; Hugh W Brock; Alexander Mazo
Journal:  Cell       Date:  2012-08-23       Impact factor: 41.582

10.  A polycomb group protein is retained at specific sites on chromatin in mitosis.

Authors:  Nicole E Follmer; Ajazul H Wani; Nicole J Francis
Journal:  PLoS Genet       Date:  2012-12-20       Impact factor: 5.917

View more
  24 in total

Review 1.  Neonatal tumours.

Authors:  S W Moore
Journal:  Pediatr Surg Int       Date:  2013-10-31       Impact factor: 1.827

Review 2.  Long non-coding RNAs and MYC association in hematological malignancies.

Authors:  Leonidas Benetatos; Agapi Benetatou; Georgios Vartholomatos
Journal:  Ann Hematol       Date:  2020-07-04       Impact factor: 3.673

Review 3.  Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.

Authors:  Goro Sashida; Atsushi Iwama
Journal:  Int J Hematol       Date:  2016-11-09       Impact factor: 2.490

4.  EBV-negative aggressive NK-cell leukemia/lymphoma: a clinical and pathological study from a single institution.

Authors:  Juehua Gao; Amir Behdad; Peng Ji; Kristy L Wolniak; Olga Frankfurt; Yi-Hua Chen
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

5.  Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1.

Authors:  Yan-Dong Wang; Yong-Jing Su; Jian-Ying Li; Xiang-Chao Yao; Guang-Jiang Liang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

6.  IGF2BP1 Promotes Proliferation of Neuroendocrine Neoplasms by Post-Transcriptional Enhancement of EZH2.

Authors:  Florian Sperling; Danny Misiak; Stefan Hüttelmaier; Patrick Michl; Heidi Griesmann
Journal:  Cancers (Basel)       Date:  2022-04-24       Impact factor: 6.575

7.  The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.

Authors:  Soo Hee Kim; Woo Ick Yang; Yoo Hong Min; Young Hyeh Ko; Sun Och Yoon
Journal:  Tumour Biol       Date:  2015-09-04

8.  YY1 regulates melanoma tumorigenesis through a miR-9 ~ RYBP axis.

Authors:  Guowei Zhao; Qiang Li; Aiqin Wang; Jian Jiao
Journal:  J Exp Clin Cancer Res       Date:  2015-06-24

9.  Interplay of H2A deubiquitinase 2A-DUB/Mysm1 and the p19(ARF)/p53 axis in hematopoiesis, early T-cell development and tissue differentiation.

Authors:  M Gatzka; A Tasdogan; A Hainzl; G Allies; P Maity; C Wilms; M Wlaschek; K Scharffetter-Kochanek
Journal:  Cell Death Differ       Date:  2015-01-23       Impact factor: 15.828

10.  MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer.

Authors:  Ayesha N Shajahan-Haq; Katherine L Cook; Jessica L Schwartz-Roberts; Ahreej E Eltayeb; Diane M Demas; Anni M Warri; Caroline O B Facey; Leena A Hilakivi-Clarke; Robert Clarke
Journal:  Mol Cancer       Date:  2014-10-23       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.